Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 613 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Function Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

NCT04699032
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Apraglutide
Drug
Lead sponsor
VectivBio AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Impact of an Orthotic Intervention in Children With Peripheral Neuropathy

NCT03655587
View directory record Official record
Conditions
Gait, Drop Foot, Chemotherapy-induced Peripheral Neuropathy, Acute Lymphocytic Leukemia, Pediatric, Rhabdomyosarcoma, Wilms Tumor
Interventions
Solid ankle foot orthotic, Resting night splint
Device
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
5 Years to 14 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 20, 2026, 8:20 AM EDT
Terminated Not applicable Interventional

OMT of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus

NCT02054650
View directory record Official record
Conditions
Chronic Low Back Pain, Type 2 Diabetes Mellitus
Interventions
Osteopathic Manual Treatment (OMT), Sham OMT
Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Phase 3 Interventional Results available

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

NCT04119843
View directory record Official record
Conditions
Known or Suspected Focal Liver Lesions, Severe Renal Impairment
Interventions
Mangoral
Drug
Lead sponsor
Ascelia Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Resveratrol and Vascular Function in CKD

NCT03597568
View directory record Official record
Conditions
Chronic Kidney Diseases, Endothelial Dysfunction
Interventions
Resveratrol, Placebo
Dietary Supplement · Other
Lead sponsor
Diana Jalal
Other
Eligibility
45 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

NCT06496217
View directory record Official record
Conditions
Renal Impairment
Interventions
MBX 2109
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet

NCT01324245
View directory record Official record
Conditions
Salt-sensitive Hypertension
Interventions
Fenoldopam
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 20, 2026, 8:20 AM EDT
Completed No phase listed Observational

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

NCT05526157
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 20, 2026, 8:20 AM EDT
Suspended Not applicable Interventional

SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)

NCT04589065
View directory record Official record
Conditions
Heart Failure, Chronic Systolic Heart Failure, Renal Failure, Cardiorenal Syndrome
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
Lenar Yessayan
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 20, 2026, 8:20 AM EDT
Recruiting Not applicable Interventional

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07059884
View directory record Official record
Conditions
Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
Interventions
Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Dublin, California • Fremont, California • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease

NCT01769963
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Research diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

NCT03318809
View directory record Official record
Conditions
Heart Failure
Interventions
AMG 986
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Tustin, California • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Resistance Exercise Training in Chronic Kidney Disease

NCT03120416
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Resistance exercise training
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Phase 2 Interventional

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05936151
View directory record Official record
Conditions
Overweight or Obesity, CKD, Type 2 Diabetes
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Chandler, Arizona • Mesa, Arizona • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 20, 2026, 8:20 AM EDT
Recruiting Phase 4 Interventional

Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes

NCT05498116
View directory record Official record
Conditions
Albuminuria
Interventions
Montelukast, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 8:20 AM EDT
Completed No phase listed Observational

A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease

NCT04487301
View directory record Official record
Conditions
Peripheral Artery Disease, End Stage Renal Disease on Dialysis
Interventions
Not listed
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
45 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Northridge, California • Coral Gables, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 20, 2026, 8:20 AM EDT
Withdrawn Not applicable Interventional

Evaluation of Kidney Function in Children With Brain Tumors

NCT00229801
View directory record Official record
Conditions
Brain Tumor
Interventions
MRI
Radiation
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function

NCT07137689
View directory record Official record
Conditions
Renal Insufficiency
Interventions
LY3537982
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Jacksonville, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

NCT02729038
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Intensive Insulin Therapy in Deceased Donors

NCT01140035
View directory record Official record
Conditions
Kidney Transplant
Interventions
Administration of continuous insulin infusion for glycemic control in brain dead donors
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Phase 2 Interventional

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

NCT00159614
View directory record Official record
Conditions
Heart Failure, Congestive, Renal Insufficiency
Interventions
KW-3902IV
Drug
Lead sponsor
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
6
States / cities
San Diego, California • Baltimore, Maryland • Ayer, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

NCT06468826
View directory record Official record
Conditions
End-Stage Renal Disease (ESRD)
Interventions
Avacopan
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 8:20 AM EDT
Terminated Phase 2 Interventional Results available

Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies

NCT03387514
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 20, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

NCT03161015
View directory record Official record
Conditions
Renal Impairment
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 20, 2026, 8:20 AM EDT